ethyl 3-bromo-2-oxoheptanoate | 13088-52-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 3-bromo-2-oxoheptanoate
• 英文别名: 3-Brom-2-oxo-heptansaeureaethylester
• CAS: 13088-52-3
• 化学式: C₉H₁₅BrO₃
• 分子量: 251.12
• InChiKey: DEIPFIRUFMGNND-UHFFFAOYSA-N

物化性质

• 沸点：
  69 °C(Press: 0.04 Torr)
• 密度：
  1.285 g/cm3(Temp: 21 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-bromo-2-oxoheptanoate 在 lithium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (E)-ethyl 2-oxo-hept-3-enoate
  参考文献：
  名称：

  Wermuth,C.G., Bulletin de la Societe Chimique de France, 1966, p. 1435 - 1444

  摘要：

  DOI：
• 作为产物：
  描述：

  正己酸乙酯 在 硫酸 、 溴 作用下， 以 四氯化碳 、 甲苯 为溶剂， 生成 ethyl 3-bromo-2-oxoheptanoate
  参考文献：
  名称：

  Wermuth,C.G., Bulletin de la Societe Chimique de France, 1966, p. 1435 - 1444

  摘要：

  DOI：

文献信息

• A highly enantioselective chemoenzymatic synthesis of syn-3-amino-2-hydroxy esters: key intermediates for taxol side chain and phenylnorstatine
  作者：J. Augusto R. Rodrigues、Humberto M.S. Milagre、Cíntia D.F. Milagre、Paulo J.S. Moran

  DOI：10.1016/j.tetasy.2005.08.015

  日期：2005.9

  Starting from the bromination of α-ketoesters to obtain 3-bromo-2-oxoalkanoates and bioreduction with Saccharomyces cerevisiae entrapped in calcium alginate pellets with double gel layers, syn-(2R,3S)-β-bromo-α-hydroxy esters were obtained regioselectively in high yields and high ee. These chiral bromohydrins were cyclized to epoxides that were transformed into oxazolidines and finally opened by acidic

  从α-酮酸酯的溴化反应开始，获得3-溴-2-氧代链烷酸酯，并用包埋在具有双层凝胶层的藻酸钙沉淀中的酿酒酵母进行生物还原，合成了顺式-（2 R，3 S）-β-溴-α-羟基酯以高产率和高ee区域选择性地获得。这些手性溴醇被环化成环氧化物，然后被转化为恶唑烷，最后通过酸性水解打开，从而以高总收率和高ee产率得到合成-（2 S，3 S）-β-氨基-α-羟基酯。在反应过程中，所有中间体的对映体过量均得以维持。
• [EN] IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY<br/>[FR] PREPARATION ET UTILISATION DE DERIVES D'IMIDAZOLE DANS LE TRAITEMENT DE L'OBESITE
  申请人：BAYER PHARMACEUTICALS CORPORAT

  公开号：WO2003040107A1

  公开（公告）日：2003-05-15

  This invention relates to substituted imidazole derivatives of formula I, which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

  本发明涉及公式I的取代咪唑衍生物，已发现其抑制食欲和诱导减重的作用。本发明还提供了合成该化合物的方法、包含该化合物的药物组合物，以及使用这些组合物诱导减重和治疗肥胖和肥胖相关疾病的方法。
• Preparation and use of imidazole derivatives for treatment of obesity
  申请人：Smith A. Roger

  公开号：US20050256167A1

  公开（公告）日：2005-11-17

  This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

  本发明涉及取代咪唑衍生物，发现其能够抑制食欲并引起减重。本发明还提供了合成该化合物的方法，包括该化合物的药物组合物，以及使用这样的组合物诱导减重和治疗肥胖和肥胖相关疾病的方法。
• Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity
  作者：Roger A. Smith、Zahra Fathi、Furahi Achebe、Christiana Akuche、Su-Ellen Brown、Soongyu Choi、Jianmei Fan、Susan Jenkins、Harold C.E. Kluender、Anish Konkar、Rico Lavoie、Ronald Mays、Jennifer Natoli、Stephen J. O’Connor、Astrid A. Ortiz、Ning Su、Christy Taing、Susan Tomlinson、Theresa Tritto、Gan Wang、Stephan-Nicholas Wirtz、Wai Wong、Xiao-Fan Yang、Shihong Ying、Zhonghua Zhang

  DOI：10.1016/j.bmcl.2007.03.011

  日期：2007.5

  Several imidazole-based cyclohexyl amides were identified as potent CB-1 antagonists, but they exhibited poor oral exposure in rodents. Incorporation of a hydroxyl moiety on the cyclohexyl ring provided a dramatic improvement in oral exposure, together with a ca. 10-fold decrease in potency. Further optimization provided the imidazole 2-hydroxy-cyclohexyl amide 45, which exhibited hCB-1 K-i = 3.7 nM and caused significant appetite suppression and robust, dose-dependent reduction of body weight gain in industry-standard rat models. (c) 2007 Elsevier Ltd. All rights reserved.
• [EN] PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE<br/>[FR] PREPARATION DE DERIVES IMIDAZOLES ET LEURS PROCEDES D'UTILISATION
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005099705A3

  公开（公告）日：2006-01-19